Situation Snapshot A new COVID-19 variant (Omicron) was recently identified in South Africa. On 11/26/21 the World Health Organization classified Omicron as a variant of concern (VOC). The decision … [Read more...] about Time For T cells: Gritstone Bio (GRTS)
Investment Update: BCRX
Update 9/30/20 Today BCRX presented updated data for its ongoing Phase 1 proof of concept study for BCX9930 in treatment-naive PNH patients. Despite this impressive and unambiguous efficacy and safety … [Read more...] about Investment Update: BCRX
With BCRX there are a number of positive features that make it an attractive investment at its current valuation (near 5-year lows; on track to have its second commercial asset approved this year), … [Read more...] about BCRX Updates
DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
In my last article I summarized my discussions with DelMar Pharmaceuticals’ (Nasdaq: DMPI) President and CEO Saiid Zarrabian and the value proposition DelMar offers investors. To recap, DelMar … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
Trade Summary Ticker: NGM (Last: $13.01) Entry: $12.70-13.0 Price Target: $14.50-20.00 Target Time-frame: 1-8 weeks Source: Trading View Trade Thesis NGM recovered as I … [Read more...] about NG-mother-effin-M
In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
Scynexis (NASDAQ: SCYX) is a clinical stage biotech company based out of New Jersey. The company has one significant drug under development in multiple indications, ibrexafungerp, for the treatment of … [Read more...] about In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
Exclusive New Feature: MS Biotech Financial Health Score
Hello there, MS Chief Pharmaceutical Officer Chris here. I am elated to share something we have been working diligently on: an objective score to help evaluate biotechnology company. As the first of … [Read more...] about Exclusive New Feature: MS Biotech Financial Health Score
Trade-Ideas for Monday, August 12th, 2019
Trade-Ideas: Thursday, Monday, August 12th, 2019Trade ideas for next week:1) BDSI $4.36* Continuation swing opportunity.* Gained 16% last week.* Released strong earnings last week with strong revenue … [Read more...] about Trade-Ideas for Monday, August 12th, 2019
MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Biopharma Stock Watch July 1st-4th
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
You must be logged in to post a comment.